Patricia Inacio PhD,  —

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

Articles by Patricia Inacio

NIH Funds Project to Speed Diagnosis of Rare Diseases

The diagnosis of rare diseases such as akylosing spondylitis (AS) is complex and often delayed. A partnership between U.S. researchers aims to use artificial intelligence to develop a software to diagnose rare diseases sooner. The four-year project, led by researchers at the University of Florida Health and the Perelman School…

New Citrate-free Taltz Becoming Available for AS Patients in US

A new and citrate-free formulation of Taltz (ixekizumab) is being made available to treat adults with active ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA) patients who have signs of inflammation. Symptoms of nr-axSpA are similar to AS, but without X-ray evidence of inflammation. This formulation of the Eli Lilly therapy was…

Rinvoq Approved in Canada for Difficult-to-treat, Active AS 

Health Canada has approved Rinvoq (upadacitinib) to treat active ankylosing spondylitis (AS) in adults who fail to respond to a biologic disease-modifying anti-rheumatic drug (DMARD) or cannot tolerate these therapies. Rinvoq, developed and marketed by AbbVie, can be used alone or in combination with non-steroidal anti-inflammatory drugs (NSAIDs), a common first…

Cosentyx Approved in US to Treat Active nr-axSpA

Cosentyx (secukinumab) has been approved in the U.S. to treat people with active non-radiographic axial spondyloarthritis (nr-axSpA), its developer, Novartis, has announced. The approval by the U.S. Food and Drug Administration (FDA) follows a similar decision by the European Commission in April. In both the…